BAY x 1351

BAY x 1351 was an investigational **monoclonal antibody** developed for the treatment of **sepsis and septic shock**. In the INTERSEPT clinical trial, it was administered as a **single intravenous infusion** at 3 mg/kg or 15 mg/kg and was designed to neutralize **tumor necrosis factor-alpha**, a central pro-inflammatory cytokine implicated in the pathobiology of septic shock. The program explored cytokine blockade as an immunomodulatory strategy in critically ill patients, but the study did not show a significant improvement in 28-day mortality versus placebo, and development appears to have been discontinued.

Other names

anti-TNF-alpha monoclonal antibodyhuman tumor necrosis factor-alpha monoclonal antibody